Anti-Müllerian Hormone: A Predictor of Successful Intrauterine Insemination

Area of Science:

• Reproductive Endocrinology
• Infertility Research
• Clinical Trials

Background:

• Anti-Müllerian hormone (AMH) is a key marker for ovarian reserve, crucial for fertility treatments.
• Serum AMH levels are frequently assessed to predict outcomes in assisted reproductive technologies.
• This study investigates AMH's role in predicting clinical pregnancy rates during intrauterine insemination (IUI).

Purpose of the Study:

• To evaluate the correlation between serum anti-Müllerian hormone (AMH) levels and clinical pregnancy (CP) rates.
• To determine the efficacy of varying ovarian stimulation protocols in conjunction with AMH levels for IUI.
• To identify predictors of successful pregnancy in women with unexplained infertility undergoing IUI.

Main Methods:

• Retrospective cohort study of 509 intrauterine insemination (IUI) cycles over four years.
• Logistic regression analysis was employed to identify predictors of clinical pregnancy (CP).
• Receiver operating characteristic (ROC) curve analysis determined the optimal AMH cut-off value (2.1 ng/mL).

Main Results:

• Cycles with clinical pregnancy (CP) showed significantly higher mean AMH values (3.7+3.5 vs. 2.2+2.1; p<0.001).
• An AMH cut-off of 2.1 ng/mL predicted higher CP rates (20.0% vs. 10.0%; p=0.041).
• Aggressive stimulation protocols (Clomid/gonadotropins/hCG) quadrupled CP rates (OR: 4.6; p<0.001).

Conclusions:

• Elevated serum AMH levels are associated with increased clinical pregnancy rates in IUI.
• More intensive ovarian stimulation protocols enhance the likelihood of pregnancy success with IUI.
• AMH serves as a valuable prognostic marker for IUI outcomes in unexplained infertility.